featured
Baricitinib, an Oral JAK1/JAK2 Inhibitor, Effective for Moderate to Severe Psoriasis
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
The British Journal of Dermatology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
A Randomized Phase 2b Trial of Baricitinib, an Oral JAK1/JAK2 Inhibitor, in Patients with Moderate-to-Severe Psoriasis
Br J Dermatol 2016 Jan 22;[EPub Ahead of Print], K Papp, MA Menter, M Raman, D Disch, DE Schlichting, C Gaich, W Macias, X Zhang, JM JanesFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.